Proactive Investors – Open Orphan #ORPH catching global attention with ‘stunning’ FLU-v results & world-first coronavirus study

Open Orphan PLC‘s (LON:ORPH) Cathal Friel and its subsidiary hVIVO’s chief scientist Dr Andrew Catchpole sat down with Proactive London’s Andrew Scott. This morning Open Orphan announced the results from a clinical trial of a broad-spectrum flu jab that they’re jointly developing have been published in a peer-reviewed journal. The data from the FLU-v 003 […]

Open Orphan #ORPH – Publication of Positive Results in Journal

Positive results from Phase IIb field study of FLU-v vaccine (FLU-v 003), which has been developed by Imutex Limited, hVIVO’s 49% joint venture with the SEEK Group. FLU-v is a first-in-class ‘universal’, broad spectrum, standalone, influenza vaccine candidate and the results have now been published in a peer review journal The publication in the Annals […]

Open Orphan #ORPH – Completion of the compulsory acquisition of remaining hVIVO shares

Open Orphan (ORPH), the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, announces that further to the announcement of 28 January 2020, the Company will shortly be posting letters to shareholders of hVIVO plc […]

Open Orphan #ORPH – Development of the World’s First Human Coronavirus Challenge Study Model

Open Orphan, the rapidly growing specialist Clinical Research Organisation (“CRO”) pharmaceutical services company whose London-based subsidiary hVIVO is the world leader in the provision of virology and vaccine challenge study services, is pleased to announce that it has commenced the development of the world’s first commercial human coronavirus challenge study model, also known as a Controlled […]

Open Orphan tip of the year update on mega contract win

by Tom Winnifrith Open Orphan (ORPH) was one of my tips of the year at a 4.6p offer. The shares are now 5.5p bid – the recent market sell off hitting it like nearly all other stocks. But the news today of a contract potentially worth £10 million plus really does slam home the message […]